Fig. 1: Generation and characterization of rLASV/IGR-CD in cultured cells.
From: A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs
A Schematic of the wild-type LASV genome used to create the recombinant control Lassa virus (rLASV-WT; top) and the locations of attenuating changes in rLASV/IGR-CD (bottom). B Vero cells or C A549 cells were exposed to rLASV-WT or rLASV/IGR-CD at the indicated MOIs, and supernatants were collected at the indicated time points. Virus titers were measured by plaque assay. D Representative images showing the morphology of plaques caused by rLASV-WT and rLASV/IGR-CD in Vero E6 cells. E Vero cells or F A549 cells were exposed to rLASV-WT or rLASV/IGR-CD at the indicated MOIs, and supernatants were collected at the indicated time points. Viral RNA levels were measured by RT-qPCR. n = 3, error bars represent standard deviation. *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005. CD codon-deoptimized; GCE genome copy equivalents; GP glycoprotein gene; GPCD codon-deoptimized glycoprotein gene; IGR intergenic region; L large segment; L large protein gene; LASV Lassa virus; MOI multiplicity of infection; NP nucleoprotein gene; PFU plaque-forming units; rLASV recombinant LASV; RT-qPCR real-time reverse transcription polymerase chain reaction; S small segment; WT wild-type; Z zinc-binding protein gene.
